Search results
Showing 46 to 60 of 69 results for parkinson's disease
complication of inactivity can accelerate disability and dependence caused by the disease and compound the burden of care in people with...
Summary of the evidence on lurasidone (Latuda) for schizophrenia in adults aged 18 and over to inform local NHS planning and decision-making
Managing medicines for adults receiving social care in the community (NG67)
This guideline covers medicines support for adults (aged 18 and over) who are receiving social care in the community. It aims to ensure that people who receive social care are supported to take and look after their medicines effectively and safely at home. It gives advice on assessing if people need help with managing their medicines, who should provide medicines support and how health and social care staff should work together.
This guideline covers mid-life approaches to delay or prevent the onset of dementia, disability and frailty in later life. The guideline aims to increase the amount of time that people can be independent, healthy and active in later life.
U-Drain for people needing night drainage of urine or dialysis fluid (MIB95)
NICE has developed a medtech innovation briefing (MIB) on U-Drain for people needing night drainage of urine or dialysis fluid .
training for sight impairment, dementia, cerebral vascular accident and Parkinson's disease. The classes are based on strong partnership...
Parkinson's disease with motor fluctuations: safinamide (ES6)
This evidence summary has been updated and replaced by NICE guideline NG71.
This guideline covers diagnosing and managing multiple sclerosis in people aged 18 and over. It aims to improve the quality of life for people with multiple sclerosis by promoting prompt and effective symptom management and relapse treatment, and comprehensive reviews.
This indicator covers the percentage of patients with moderate or severe frailty and/or multimorbidity who have received a medication review in the last 12 months which is structured, has considered the use of a recognised tool and taken place as a shared discussion. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM186
Excessive daytime sleepiness in Parkinson's disease: modafinil (ESUOM48)
This evidence summary has been updated and replaced by NICE guideline NG71.
Parkinson's disease in over 20s: diagnosis and management (CG35)
This guidance has been updated and replaced by NICE guideline NG71.
Multiple long-term conditions: multimorbidity register (IND205)
This indicator covers the practice can produce a register of people with multimorbidity who would benefit from a tailored approach to care. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM184
Personal KinetiGraph for remote clinical management of Parkinson's disease (MIB258)
This advice has been updated and replaced by NICE diagnostics guidance 51.
Parkinson's disease with end-of-dose motor fluctuations: opicapone (ES9)
This evidence summary has been updated and replaced by NICE guideline NG71.
This guideline covers care and support for adults with cerebral palsy. It aims to improve health and wellbeing, promote access to services and support participation and independent living.